Skip to main content
. 2015 Sep 18;2:131–142. doi: 10.2147/JHC.S81309

Table 1.

Clinical studies of circulating IGF-I in CLDs

Study Year Country Type of disease Study design Sample size Correlation with liver dysfunction Results
Kaseb et al136,137 2011 USA CLDs Prospective cohort 288 cases + ↓ IGF-I
Rehem and El-Shikh115 2011 Egypt and HCC Case-control 20 HCC
60 liver cirrhosis
20 controls		 + ↓ IGF-I
Su et al139 2010 Taiwan Case-control 65 cases
165 controls		 + ↓ IGF-I (P<0.001)
Lorenzo-Zúñiga et al112 2007 Spain Cohort 40 HCV + ↓ IGF-I
Elsammak et al110 2006 Egypt Case-control 30 HCC
30 HCV without chronic SHF
30 HCV with chronic SHF
30 controls		 + ↓ IGF-I (P<0.001)
Stuver et al138 2000 USA Case-control 73 HCC
25 liver metastases
111 controls		 + Serum IGF-I
(P<0.0001)
Arturi et al101 2011 Italy Steatosis and NASH Case-control 308 nondiabetic cases
195 nondiabetic controls		 + ↓ IGF-I (P=0.001)
Völzke et al102 2009 Germany Cohort 3,863 cases + ↓ IGF-I
Ronsoni et al116 2013 Brazil Cirrhosis Cross-sectional 74 cases + ↓ IGF-I
Castro et al107 2013 Brazil Case-control 25 cases
7 controls		 + ↓ IGF-I (P<0.05)
Dehghani et al108 2012 Iran Case-control 45 cases
38 controls		 + ↓ IGF-I
Sandahl et al117 2011 Denmark Case-control 8 cases
8 controls		 + ↓ IGF-I
Jeyaratnaganthan et al111 2010 Denmark Case-control 43 cases
11 controls		 + ↓ IGF-I
(P<0.05)
Assy et al105 2008 Israel Case-control 53 cases
10 controls		 + ↓ IGF-I
Wu et al119 2004 People’s Republic of China Case-control 44 cases
38 controls		 + ↓ IGF-I
Vyzantiadis et al118 2003 Greece Case-control 40 cases
20 controls		 + ↓ IGF-I
Mazziotti et al113 2002 Italy Prospective cohort 114 HCV cases + ↓ IGF-I in patients developed HCC
Donaghy et al109 2002 UK Cohort 50 cases + ↓ IGF-I/GH
Assy et al104 1998 Israel Cohort 15 cases + ↓ IGF-I and ↑ after rhGH
Caregaro et al106 1997 Italy Cohort 64 cases + ↓ IGF-I (P<0.01)
Møller et al114 1993 Denmark Case-control 36 cases 34
controls		 + ↓ IGF-I

Abbreviations: CLDs, chronic liver diseases; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NASH, nonalcoholic steatohepatitis; SHF, schistosomal hepatic fibrosis; IGF, insulin-like growth factor; GH, growth hormone; rhGH, recombinant human growth hormone.